The estimated Net Worth of Kevin T Conroy is at least $63 Million dollars as of 22 May 2024. Mr. Conroy owns over 660 units of Exact Sciences stock worth over $42,319 and over the last 16 years he sold EXAS stock worth over $44,264,698. In addition, he makes $18,716,500 as Chairman of the Board, President, and Chief Executive Officer at Exact Sciences.
Kevin has made over 90 trades of the Exact Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 660 units of EXAS stock worth $42,319 on 22 May 2024.
The largest trade he's ever made was exercising 633,075 units of Exact Sciences stock on 11 November 2016 worth over $797,675. On average, Kevin trades about 38,129 units every 35 days since 2009. As of 22 May 2024 he still owns at least 660 units of Exact Sciences stock.
You can see the complete history of Mr. Conroy stock trades at the bottom of the page.
Kevin T. Conroy serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Conroy has served as our President and Chief Executive Officer since April 2009, as a director since March 2009 and as Chairman of our Board of Directors since March 2014. Mr. Conroy served as president and chief executive officer of Third Wave Technologies, Inc., a molecular diagnostics company, from December 2005 until the acquisition of Third Wave by Hologic, Inc. in July 2008. He joined Third Wave in July 2004 and served as general counsel until December 2005. Prior to joining Third Wave, Mr. Conroy held leadership positions at GE Healthcare and practiced intellectual property law in private practice. Mr. Conroy also serves as a director of Epizyme, Inc., a clinical-stage biopharmaceutical company (NASDAQ: EPZM). He earned a bachelor's degree in electrical engineering at Michigan State University and a JD from the University of Michigan.
As the Chairman of the Board, President, and Chief Executive Officer of Exact Sciences, the total compensation of Kevin Conroy at Exact Sciences is $18,716,500. There are no executives at Exact Sciences getting paid more.
Kevin Conroy is 54, he's been the Chairman of the Board, President, and Chief Executive Officer of Exact Sciences since 2014. There are 13 older and 9 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
Kevin's mailing address filed with the SEC is C/O ALIGN TECHNOLOGY INC., 410 N. SCOTTSDALE RD., SUITE 1300, TEMPE, AZ, 85288.
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania, and Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Exact Sciences executives and other stock owners filed with the SEC include: